Case Report
Vancomycin Therapy and the Progression of Methicillin-resistant Staphylococcus aureus Vertebral Osteomyelitis
Abstract
Vancomycin therapy is the standard treatment for methicillin-resistant Staphylococcus aureus (MRSA), the most common cause of vertebral osteomyelitis, an increasingly frequent complication of nosocomial bacteremia. We report five recent cases suggesting that, while giving the appearance of success by conventional clinical and laboratory criteria (eg, resolution of fever and leukocytosis), vancomycin monotherapy may in fact be insufficient to prevent or reverse the progression of hematogenous MSRA vertebral osteomyelitis. A review of the literature and possible therapeutic alternatives are also discussed.This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.
References
1. Torda AJ, Gottlieb T, Bradbury R. Pyogenic vertebral Osteomyelitis: analysis of 20 cases and review.Clin Infect Dis 1995;20:320–8.
2. Lew DP, Waldvogel FA. Osteomyelitis. N Engl J Med 1997;336:999–1007.
3. Waldvogel FA: Staphylococcus aureus (Including Staphylococcal Toxic Shock), in Mandell GL, Bennett JE, Dolin R (eds), Principles and Practice of Infectious Diseases. Philadelphia, Churchill Livingstone, ed 5, pp 2069–2092.
4. Aspinall SL, Friedland DM, Yu VL, et al. Recurrent methicillin-resistant Staphylococcus aureus osteomyelitis: combination antibiotic therapy with evaluation by serum bactericidal titers. Ann Pharm1995;29:694–697.
5. Khatib R, Riederer KM, Held M, et al. Protracted and recurrent methicillin-resistant Staphylococcus aureus bacteremia despite defervescence with vancomycin therapy. Scand J Infect Dis 1995;27:529–532.
6. Priest DH, Peacock JE. Hematogenous Vertebral Osteomyelitis (HVO) Due to Staphylococcus Aureus (SA) in the Adult: Clinical Features and Therapeutic Outcomes (abstract 72). 39th Annual Meeting of the Infectious Disease Society of America. San Francisco: October 25–28, 2001.
7. Graziani AL, Lawson LA, Gibson GA, et al. Vancomycin concentrations in infected and noninfected human bone. Antimicrob Agents Chemother 1988;32:1320–1322.
8. Webb LX, Holman J, deAraujo B, et al. Antibiotic resistance in staphylococci adherent to cortical bone. J Orthop Trauma 1994;8:28–33.
9. Cantu TG, Yamanaka-Yuen NA, Lietman PS. Serum vancomycin concentrations: reappraisal of their clinical value. Clin Infect Dis 1994;18:533–543.
10. Ringberg H, Thoren A, Lilja B. Metastatic complications of Staphylococcus aureus septicemia: to seek is to find. Infection 2000;28:132–136.
11. Tice AD, Hoaglund PA, Shoultz DA. Risk factors and treatment outcomes in osteomyelitis. J Antimicrob Chemother 2003;51:1261–1268.
12. Small PM, Chambers HF. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother 1990;34:1227–1231.
13. Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 1991;115:674–680.
14. Gonzalez C, Rubio M, Romero-Vivas J, et al. Bacteremic Pneumonia Due to Staphylococcus aureus: a comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms.Clin Infect Dis 1999;29:1171–1177.
15. Jensen AG, Espersen F, Skinhoj P, et al. Bacteremic Staphylococcus aureus spondylitis. Arch Intern Med 1998;158:509–517.
16. Moellering RC Jr. Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med 2003;138:135–142
